Neurofibromatosis type 1 (NF1) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070423

This document outlines details of PBS-subsidised selumetinib for patients with neurofibromatosis type 1 (NF1).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Neurofibromatosis type 1 (NF1) quick reference

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB370 form	Written Electronic S85: selumetinib	No	OPA	Must be treated by a: specialist physician with expertise in neurofibromatosis a medical practitioner in consultation with a specialist physician with expertise in neurofibromatosis if attendance is not possible due to geographic isolation	Yes
Grandfather PB371 form	Written Electronic S85: selumetinib	No	OPA	Must be treated by a: specialist physician with expertise in neurofibromatosis a medical practitioner in consultation with a specialist physician with expertise in neurofibromatosis if attendance is not possible due to geographic isolation	Yes
Continuing	Telephone Electronic S85: selumetinib	No	OPA	Must be treated by a: specialist physician with expertise in neurofibromatosis a medical practitioner in consultation with a specialist physician with expertise in neurofibromatosis if attendance is not possible due to geographic isolation	Yes